Pacira BioSciences, Inc. (PCRX) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2026
Loading P/E history...
PCRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Pacira BioSciences, Inc. (PCRX) trades at a price-to-earnings ratio of 147.8x, with a stock price of $23.64 and trailing twelve-month earnings per share of $0.23.
The current P/E is roughly in line with its 5-year average of 139.7x. Over the past five years, PCRX's P/E has ranged from a low of 15.5x to a high of 889.5x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PCRX trades at a 562% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PCRX commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PCRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PCRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 13.3Lowest | - | +431% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $8B | 25.5 | 1.11Best | -25% | |
| $100B | 21.6 | - | +31% | |
| $113B | 35.0 | 2.36 | +8% | |
| $16B | 23.5 | - | -20% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PCRX Historical P/E Data (2015–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $22.60 | $0.12 | 188.3x | -23% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $25.88 | $0.15 | 172.5x | -29% |
| FY2025 Q3 | $25.77 | $0.45 | 57.3x | -76% | |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $28.61 | $1.29 | 22.2x | -91% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $29.22 | $1.41 | 20.8x | -91% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $33.74 | $0.79 | 42.8x | -82% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $30.68 | $0.09 | 340.9x | +40% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $38.61 | $0.31 | 124.5x | -49% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $53.19 | $0.41 | 129.7x | -47% |
| FY2022 Q2 | $58.30 | $0.82 | 71.1x | -71% | |
| FY2022 Q1 | $76.32 | $0.84 | 90.9x | -63% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $60.17 | $0.92 | 65.4x | -73% |
Average P/E for displayed period: 243.0x
See PCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
Is PCRX stock overvalued or undervalued?
PCRX trades at 147.8x P/E, near its 5-year average of 139.7x. The 70th percentile ranking places valuation within normal historical bounds.
How does PCRX's valuation compare to peers?
Pacira BioSciences, Inc. P/E of 147.8x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is PCRX's PEG ratio?
PCRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2026.